BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18663758)

  • 1. Dose finding - a challenge in statistics.
    Bretz F; Hsu J; Pinheiro J; Liu Y
    Biom J; 2008 Aug; 50(4):480-504. PubMed ID: 18663758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating potential benefits of dose-exposure-response modeling for dose finding.
    Hsu CH
    Pharm Stat; 2009; 8(3):203-15. PubMed ID: 19629954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis of dose-finding studies combining multiple comparisons and modeling procedures.
    Pinheiro J; Bornkamp B; Bretz F
    J Biopharm Stat; 2006; 16(5):639-56. PubMed ID: 17037263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining multiple comparisons and modeling techniques in dose-response studies.
    Bretz F; Pinheiro JC; Branson M
    Biometrics; 2005 Sep; 61(3):738-48. PubMed ID: 16135025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
    Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
    J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An improved method of evaluating drug effect in a multiple dose clinical trial.
    Shen L
    Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive designs for Phase I dose-finding studies.
    Zhou Y
    Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of the biometrician in dosage finding].
    Schneider B
    Arzneimittelforschung; 1977 Feb; 27(2A):257-64. PubMed ID: 577172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding the maximum safe dose level for heteroscedastic data.
    Tamhane AC; Logan BR
    J Biopharm Stat; 2004 Nov; 14(4):843-56. PubMed ID: 15587967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ordered multiple comparisons with the best and their applications to dose-response studies.
    Strassburger K; Bretz F; Finner H
    Biometrics; 2007 Dec; 63(4):1143-51. PubMed ID: 17489969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging in clinical trials: rationale and proposed use with placebo or positive controls.
    Freston JW
    Am J Gastroenterol; 1986 May; 81(5):307-11. PubMed ID: 3706243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dose-response relationship: relevance for medical practice].
    Klinkhardt U; Harder S
    Med Klin (Munich); 2000 May; 95(1 Spec No):9-14. PubMed ID: 10851842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A note on multiple testing procedures in dose finding.
    Bauer P
    Biometrics; 1997 Sep; 53(3):1125-8. PubMed ID: 9333343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-stage design for dose-finding that accounts for both efficacy and safety.
    Dragalin V; Fedorov VV; Wu Y
    Stat Med; 2008 Nov; 27(25):5156-76. PubMed ID: 18680164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
    Pinheiro J
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
    [No Abstract]   [Full Text] [Related]  

  • 20. Prediction approaches to sequentially searching for an optimal dose.
    Shih WJ
    Biometrics; 1989 Jun; 45(2):623-8. PubMed ID: 2669990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.